Evidence map›Paper›PMID 24714069›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2014

African ancestry influences CCR5 -2459G>A genotype-associated virologic success of highly active antiretroviral therapy.

Vinay K Cheruvu, Robert P Igo, Richard J Jurevic, David Serre, Peter A Zimmerman, Benigno Rodriguez, Rajeev K Mehlotra

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Vinay K Cheruvu*Department of Biostatistics, Environmental Health Sciences, and Epidemiology, College of Public Health, Kent State University, Kent, OH; †Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH; ‡Department of Biological Sciences, Case Western Reserve University School of Dental Medicine, Cleveland, OH; §Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH; ‖Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH; and ¶Department of Medicine, Division of Infectious Diseases and HIV Medicine, Case Western Reserve University School of Medicine, Cleveland, OH (Dr Richard J. Jurevic, DDS, PhD, is now with the Department of Oral Diagnostics, School of Dentistry, West Virginia University, Morgantown, WV).
Robert P Igo
Richard J Jurevic
David Serre
Peter A Zimmerman
Benigno Rodriguez
Rajeev K Mehlotra
Case Western Reserve University · USCenter for Global Health · USCase Comprehensive Cancer CenterKent State University · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024989 · NCRR · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B · 2007 to 2011
$53.7M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Sharon L. Hillier, JONATHAN KARN · 1994 to 2026
$50.0M
Proj. 4-The Genetic Variation of Innate Immune Genes w/Oral Manifestations of HIVP01DE019759 · NIDCR · CASE WESTERN RESERVE UNIVERSITY · PI CHANCE, MARK R · 2009 to 2013
$9.0M
NCRR NIH HHS UL1 RR024989NCRR NIH HHS UL1RR024989NIAID NIH HHS AI36219NIAID NIH HHS P30 AI036219NIDCR NIH HHS 1P01DE019759NIDCR NIH HHS P01 DE019759NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

introductionIn a North American, HIV-positive, highly active antiretroviral therapy (HAART)-treated, adherent cohort of self-identified white and black patients, we previously observed that chemokine (C-C motif) receptor 5 (CCR5) -2459G>A genotype had a strong association with time to achieve virologic success (TVLS) in black but not in white patients.

methodsUsing 128 genome-wide ancestry informative markers, we performed a quantitative assessment of ancestry in these patients (n = 310) to determine (1) whether CCR5 -2459G>A genotype is still associated with TVLS of HAART when ancestry, not self-identified race, is considered and (2) whether this association is influenced by varying African ancestry.

resultsWe found that the interaction between CCR5 -2459G>A genotype and African ancestry (≤ 0.125 vs. ≥ 0.425 and <0.71 vs. ≥ 0.71) was significantly associated with TVLS (GG compared with AA, P = 0.044 and 0.018, respectively). Furthermore, the association between CCR5 -2459G>A genotype and TVLS was stronger in patients with African ancestry ≥ 0.71 than in patients with African ancestry ≥ 0.452, in both Kaplan-Meier (log-rank P = 0.039 and 0.057, respectively, for AA, GA, and GG) and Cox proportional hazards regression (relative hazard for GG compared with AA 2.59 [95% confidence interval: 1.27 to 5.22; P = 0.01] and 2.26 [95% confidence interval: 1.18 to 4.32; P = 0.01], respectively) analyses.

conclusionsWe observed that the association between CCR5 -2459G>A genotype and TVLS of HAART increased with stronger African ancestry. Understanding the genomic mechanisms by which African ancestry influences this association is critical and requires further studies.

Indexed as

Antiretroviral Therapy, Highly ActiveAdultAnti-Retroviral AgentsBlack or African AmericanCohort StudiesFemaleGenotypeHIV InfectionsHumansMaleMiddle AgedReceptors, CCR5Time FactorsTreatment OutcomeViral LoadAnti-Retroviral AgentsCCR5 protein, humanReceptors, CCR5

Identifiers

PMID24714069
PMCPMC3996453
OpenAlexW2036724148

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.